Dr. Nabil Adra, MD

Dr. Adra practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Adra's NPI, 1811285893, was assigned on July 12, 2011. Dr. Adra holds Indiana license 01078274A.

Dr. Adra's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Adra's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Adra is also affiliated with IU Health Ball Memorial Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Adra to 3 more hospitals, 2 group practices and clinics, 1 behavioral health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Adra practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Adra's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Adra is licensed in Indiana.

CMS data shows 930 Medicare services from Dr. Adra across 5 procedure codes in 2024, for 285 Medicare patients. Medicare paid $58,549 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 285 Medicare patients who saw Dr. Adra in 2024. The largest group is 65 to 74, with 140 patients. 75% of them have cancer, and 75% have high blood pressure. 5% are also on Medicaid. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Adra's median patient age at 70, with 13% women.

In 2024, Dr. Adra wrote 1,344 Medicare Part D claims for 152 patients. 65% of them were for generic drugs. CMS names the drug for 1,180 of them, across 27 drugs with 11 or more claims each, at $5,663,544 in total drug cost. In 2023, CMS named 1,270 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 56 out of 100 for Dr. Adra for performance year 2024, reported individually. Dr. Adra accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Adra as offering telehealth.

Dmand AI links 73 papers to Dr. Adra, published from 2015 to 2025. 2022 was the busiest year, with 11. The most frequent topics are Testicular Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Salvage Therapy. Dr. Adra has published most often in Clin Genitourin Cancer. Dr. Adra's most frequent co-authors are Lawrence H. Einhorn, MD, Costantine Albany, MD and Timothy A. Masterson, MD.

Dmand AI links Dr. Adra to 10 clinical trials, 4 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 42 general payments to Dr. Adra from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Merck Sharp & Dohme Corporation paid the most, $13,022.